Edlund P, Ahlgren J, Bjerre K, Andersson M, Bergh J, Mouridsen H, et al. Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1. AO [Internet]. 2011 Apr. 1 [cited 2026 Apr. 30];50(3):329-37. Available from: https://medicaljournalssweden.se/actaoncologica/article/view/31961